Parabilis Medicines Inc

D

الأسعار متأخرة 15 دقيقة

القطاع: الرعاية الصحية

الصناعة: Biotechnology

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helicalpeptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between -catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.